2008

Opacity Factor Activity and Epithelial Cell Binding by the Serum Opacity Factor Protein of Streptococcus pyogenes Are Functionally Discrete

C. M. Gillen
University of Wollongong

H. S. Courtney
University of Tennessee Health Science Center, USA

K. Schulze
Helmholtz Centre for Infection Research, Germany

M. Rohde
Helmholtz Centre for Infection Research, Germany

Mark R. Wilson
University of Wollongong, mrw@uow.edu.au

See next page for additional authors

Publication Details
This article was originally published as Gillen, CM et al, Opacity Factor Activity and Epithelial Cell Binding by the Serum Opacity Factor Protein of Streptococcus pyogenes Are Functionally Discrete, Journal of Biological Chemistry, 283(10), 2008, 6359-6366.
Opacity Factor Activity and Epithelial Cell Binding by the Serum Opacity Factor Protein of Streptococcus pyogenes Are Functionally Discrete

Abstract
Serum opacity factor (SOF) is a unique multifunctional virulence determinant expressed at the surface of Streptococcus pyogenes and has been shown to elicit protective immunity against GAS infection in a murine challenge model. SOF consists of two distinct domains with different binding capacities: an N-terminal domain that binds apolipoprotein AI and a C-terminal repeat domain that binds fibronectin and fibrinogen. The capacity of SOF to opacify serum by disrupting the structure of high density lipoproteins may preclude its use as a vaccine antigen in humans. This study generated mutant forms of recombinant SOF with reduced (100-fold) or abrogated opacity factor (OF) activity, for use as vaccine antigens. However, alterations introduced into the N-terminal SOF peptide (SOFFn) by mutagenesis to abrogate OF activity, abolish the capacity of SOF to protect against lethal systemic S. pyogenes challenge in a murine model. Mutant forms of purified SOFFn peptide were also used to assess the contribution of OF activity to the pathogenic processes of cell adhesion and cell invasion. Using latex beads coated with full-length SOF, SOFFn peptide, or a peptide encompassing the C-terminal repeats (FnBD), we demonstrate that adhesion to HEp-2 cells is mediated by both SOFFn and FnBD. The HEp-2 cell binding displayed by the N-terminal SOFFn peptide is independent of OF activity. We demonstrate that while the N terminus of SOF does not directly mediate intracellular uptake by epithelial cells, this domain enhances epithelial cell uptake mediated by full-length SOF, in comparison to the FnBD alone.

Keywords
Streptococcus, Pyogenes, Opacity, CMMB

Disciplines
Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences

Publication Details
This article was originally published as Gillen, CM et al, Opacity Factor Activity and Epithelial Cell Binding by the Serum Opacity Factor Protein of Streptococcus pyogenes Are Functionally Discrete, Journal of Biological Chemistry, 283(10), 2008, 6359-6366.

Authors
C. M. Gillen, H. S. Courtney, K. Schulze, M. Rohde, Mark R. Wilson, A. M. Timmer, C. A. Guzman, V. Nizet, G. S. Chhatwal, and Mark J. Walker

This journal article is available at Research Online: http://ro.uow.edu.au/scipapers/108
Opacity factor activity and epithelial cell binding by the serum opacity factor protein of *Streptococcus pyogenes* are functionally discrete

Christine M. Gillen⁸¹, Harry S. Courtney⁸², Kai Schulze⁸, Manfred Rohde⁸, Mark R. Wilson⁹, Anjuli M. Timmer⁹, Carlos A. Guzman⁸, Victor Nizet⁹, G.S. Chhatwal⁸, and Mark J. Walker⁸³

⁸School of Biological Sciences, University of Wollongong, NSW, Australia; ⁹Veterans Affairs Medical Center and Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA ⁸Department of Vaccinology, Helmholtz Centre for Infection Research, Braunschweig, Germany * Department of Microbial Pathogenicity, Helmholtz Centre for Infection Research, Braunschweig, Germany ⁹Department of Pediatrics, Division of Pharmacology and Drug Discovery, University of California, San Diego, La Jolla, CA, USA.

Running Title: ApoAI and epithelial cell binding by SOF are functionally discrete

**SUMMARY**

Serum opacity factor (SOF) is a unique multifunctional virulence determinant expressed at the surface of *S. pyogenes* and has been shown to elicit protective immunity against GAS infection in a murine challenge model. SOF consists of two distinct domains with different binding capacities: an N-terminal domain which binds apolipoprotein AI, and a C-terminal repeat domain that binds fibronectin and fibrinogen. The capacity of SOF to opacify serum by disrupting the structure of high density lipoproteins may preclude its use as a vaccine antigen in humans. This study generated mutant forms of recombinant SOF with reduced (100-fold) or abrogated opacity factor (OF) activity, for use as vaccine antigens. However, the structural alterations introduced into the N-terminal SOF peptide (SOFΔFn) by mutagenesis to abrogate OF activity, abolish the capacity of SOF to protect against lethal systemic *S. pyogenes* challenge in a murine model. Mutant forms of purified SOFΔFn peptide were also used to assess the contribution of OF activity to the pathogenic processes of cell adhesion and cell invasion. Using latex beads coated with full-length SOF, SOFΔFn peptide or a peptide encompassing the C-terminal repeats (FnBD), we demonstrate that adhesion to HEp-2 cells is mediated by both SOFΔFn and FnBD. The HEp-2 cell binding displayed by the N-terminal SOFΔFn peptide is independent of OF activity. We demonstrate that while the N-terminus of SOF does not directly mediate intracellular uptake by epithelial cells, this domain enhances epithelial cell uptake mediated by full-length SOF, in comparison to the FnBD alone.

**INTRODUCTION**

*Streptococcus pyogenes* (group A streptococcus; GAS⁴) is an important human pathogen responsible for a wide variety of skin and mucosal infections ranging from pharyngitis and impetigo to more severe invasive infections, such as necrotizing fasciitis and streptococcal toxic shock-like syndrome (1-3). The serum opacity factor (SOF) is a large protein of ~110 kDa which is expressed at the cell surface by approximately half of all clinical isolates (4,5). Similar to a number of other surface proteins expressed by *S. pyogenes*, SOF binds fibronectin via a C-terminal repeated domain (FnBD) (6-8), a function that has been implicated in the adhesion of GAS to epithelial cells (9). In contrast to the conserved C-terminus, the N-terminus of SOF (SOFΔFn) is highly variable exhibiting ~55% identity between different serotypes of *S. pyogenes*. The N-terminal domain of SOF was originally thought to cleave apolipoprotein A1 (apoAI) in human serum leading to the precipitation of high-density lipoproteins (HDLs) (10,11). However, it has recently been demonstrated that the OF activity of SOF is not enzymatic; rather, the direct binding of apoAI by SOF triggers the release of the HDL lipid cargo of apoAI, initiating the opacity reaction (12). This OF domain of SOF promotes GAS invasion of epithelial cells (13), but it is not known whether the OF activity itself or a discrete domain within the N-terminus of SOF contributes to this phenotype. SOF is a virulence determinant of GAS, with insertional inactivation or allelic replacement of sof reducing mortality in an intraperitoneal and subcutaneous murine infection model (13,14). SOF is also a vaccine candidate - parenteral immunization of mice with SOF...
It is not known what physiological effect that the precipitation of HDL would have upon the human host or how the interaction of SOF with apoAI contributes to the pathogenesis of GAS. ApoAI exerts a potent anti-inflammatory effect by preventing contact between infected T-cells and monocytes thereby inhibiting cytokine production (namely TNF-alpha and IL-1) in monocytes (16). In vitro, both HDL and apoAI exert anti-inflammatory effects against the potent bacterial endotoxins, Gram-negative LPS and Gram-positive lipoteichoic acid, binding strongly to both endotoxins and inhibiting the production of TNF-α (17-19). In vivo, transgenic animal studies of the toxicity of LPS have shown that expression of human apoAI transgenes protected mice from a lethal dose of LPS (20). ApoAI also possesses specific anti-bacterial and anti-viral properties (21-23).

The administration of active SOF protein as a vaccine when the downstream effects of disrupting HDL and its activity in vivo are unknown would not be recommended, as the most effective protection against GAS infection is delivered when the SOF protein is administered parenterally (15) and the localized depletion of HDL may reduce the body’s defense against other pathogens or may result in inflammation at the site of immunization. Thus, before SOF could be used as a potential vaccine antigen (alone or as part of a multivalent vaccine formulation) it would be prudent to eliminate the OF activity of the protein. To this end, this study generated mutant forms of recombinant SOF protein with attenuated or eliminated OF activity, for use as vaccine formulations. These mutant SOF proteins are also been used to further delineate OF activity and cell binding activity within the N-terminus of SOF.

MATERIALS AND METHODS

Site directed mutagenesis - A pQE30 based vector encoding a fusion protein of residues 33–872 of SOF from a M75 GAS strain (lacking signal sequence and fibronectin binding repeat region, pSOF75ΔFn) (24), was used as the template for all mutagenesis reactions. Site directed mutagenesis was performed as previously described (25). Primers for site directed mutagenesis are given in supplementary material Table 1. Two mutagenesis strategies were employed, amino acid residues were substituted with alanine (single residues up to 5 residues) and small deletions were made within rSOF75ΔFn. Deletions within rSOF75ΔFn were generated by using site directed mutagenesis to introduce two AvrII restriction sites flanking the region to be deleted, followed by digestion with AvrII. The digested fragments were then separated by agarose gel electrophoresis, and the DNA fragment containing the portion of pSOF75ΔFn of interest was extracted from the gel and re-ligated.

Expression and purification of wildtype and mutant forms of rSOF75 and rSOF75ΔFn protein - Large-scale expression and purification of rSOF75 proteins was conducted essentially according to manufacturer’s instructions (Qiagen), and has been previously described (13,26). To ensure correct refolding of proteins was achieved, wildtype purified proteins were subsequently tested for opacity factor activity using an agarose overlay method (7).

Structural characterisation of wildtype and mutant forms of rSOF75ΔFn protein - To determine the structural integrity of mutant rSOF75ΔFn proteins in comparison to the wildtype, a comparison of the secondary structure of wildtype and mutant rSOF75ΔFn proteins was conducted using circular dichroism (CD) spectroscopy. CD spectra were acquired using a Jasco J-810 Spectropolarimeter (Jasco). Experiments were conducted at room temperature with proteins at a concentration of approximately 0.2 mg/ml in 10mM sodium phosphate buffer, pH 7.5 containing 50% trifluoroethanol (27,28). Far UV spectra were recorded from 190-250 nm in a 0.1 cm path length cell (Starna) containing 400 μl of protein solution. The data shown represents an average of ten scans, corrected for a buffer baseline. Mean residue ellipticity (MRE; [θ]) was calculated using the following formula (29):

\[
MRE \ [\theta] = \frac{\theta \times 100 \times \text{molecular weight}}{\text{conc (mg/ml)} \times \text{path length} \times 1000 \times \text{no. of residues}}
\]

The α-helical content of wildtype and mutant forms of rSOF75ΔFn was calculated from the
MRE value at 222 nm using the following equation as described by (30).

\[
\%\text{\alpha-Helix} = \frac{\text{MRE}[\theta]_{222} - 2340}{30300} \times 100
\]

**Opacity Activity Assays** – Qualitative opacity factor assays were conducted using the serum agarose overlay method (7). The serum overlay method permits visual confirmation of OF activity, as binding of apoA1 by SOF causes precipitation of apoAI and HDL, which appears as an opaque white band on the solid serum/agarose medium. Data is presented as an inversion of the actual blot with opacity activity appearing as a dark band on a light background. Quantitative opacity factor assays were conducted using purified HDL or human serum using the method of Courtney et al. (12), with opacification measured as absorbance at 405nm.

**ApoAI binding capacity** – Wells of a microtiter plate were coated with 20 µg/ml rSOF75 protein or gelatin in 0.01 M sodium bicarbonate for 1 h at 37°C. Plates were washed with PBS and blocked with gelatin (1 mg/ml in PBS) for 1 h at 37°C, 100 µl of biotinylated (Pierce) apoAI (Calbiochem) was added and incubated at 37°C for 1 h. Following washing 100 µl of avidin-peroxidase (0.5 µg/ml) was added to the wells and incubated at 37°C for 1 h. the plates were washed and 3,3', 5,5'-tetramethylbenzidine substrate added. Colour development was stopped using 1 M phosphoric acid and the absorbance at 650nm was recorded. Binding was assayed in triplicate, binding to gelatin was considered non-specific and was subtracted from the readings.

**Interaction of SOF coated latex beads with HEp-2 cells** - Assays of the interaction of SOF coated latex beads with HEp-2 cells were conducted as per previously published methods (13,31,32). Preliminary assays were conducted in DMEM HEPES supplemented with either 10% FCS or 1% FCS. However, differential binding was observed between these two assay conditions, the rSOF75ΔFn only mediated binding to HEp-2 cells when incubated in DMEM HEPES 1% FCS, and thus these conditions were used for all further latex bead adherence assays. The efficiency of protein loading on to latex beads was measured by FLUOstar fluorescent plate reader (BMG Labtech) using anti-SOF75 rabbit serum and fluorescent labeling with goat anti-rabbit Alexa 488 (green) (Molecular Probes) (data not shown), protein loading efficiency was found to be comparable for all protein domains. To determine the effect of exogenous addition of the rFNBD domain on the adhesion and internalization of rSOFΔFn coated latex beads, purified rFnBD at 1, 5 or 10 µg/ml was pre-incubated with the HEp-2 cells for 1 h prior to addition of the coated latex beads, and was maintained throughout the subsequent 4 h incubation with the latex beads.

**Confocal microscopy studies** - HEp-2 cells (after incubation with the coated latex beads) were fixed for 30 min on ice in 500 µl/well of pre-chilled 4% paraformaldehyde in PBS, and then washed twice in PBS. Cells were then blocked by the addition of 200 µl/well of PBS containing 10% foetal calf serum and incubated for 30 min at room temperature. The blocking solution was then removed and the cells were incubated with either protein-G purified rabbit polyclonal anti-SOF75 antibodies (26) (30 µg) or rabbit polyclonal anti-FnBD antibodies (1:100 dilution) for 45 min at room temperature. Following washing with PBS, cells were incubated with goat anti-rabbit Alexa 488 diluted 1:400 in PBS containing 10% BSA (Molecular Probes) for 1 h at room temperature and subsequently washed with PBS. Cells were permeabilized with 200 µl/well of 0.1% (v/v) triton X-100 in PBS for 30 min on ice, washed in PBS, followed by storage at 4°C overnight. The following day, cells were treated with goat anti-rabbit Alexa 633 diluted 1:400 in PBS containing 10% BSA (Molecular Probes) for 1 h and washed three times in PBS. Cells were then mounted onto a glass slide using Mowiol solution (Calbiochem). Images were recorded using a Leica TCS SP confocal microscope mounted on a Leica DM IRBE inverted microscope with Leica TCS NT software (Version 2.61; Leica Microsystems).

**Mouse immunization and challenge** - To determine the protective efficacy of rSOF75ΔFn proteins challenge studies were performed. BALB/c mice (n=10) were immunized
subcutaneously with 25 µg of wildtype or mutant forms of rSOF75ΔFn protein in incomplete Freund's adjuvant. Control mice received a subcutaneous injection of PBS. After 2 weeks, the mice were boosted with an intramuscular injection of another 25 µg of each protein in PBS. Control mice received a PBS injection. Two weeks after the booster injections, all mice were challenged by an intraperitoneal injection of ~1 x 10⁹ CFU of the SOF-positive M49 GAS strain 591 (33). The number of surviving mice was recorded daily. Moribund mice were sacrificed and recorded as dead.

Serum samples were collected on days 0 and 28, and stored at −20°C prior to determination of rSOF75ΔFn-specific antibodies. In brief, 96-well Nunc-Immuno MaxiSorp assay plates (Nunc) were coated with 2 µg/ml of wildtype rSOF75ΔFn in coating buffer (bicarbonate, pH 9.4). After overnight incubation at 4°C, plates were blocked with 1% BSA in PBS (pH 7.4) for 1 h at 37°C. Serial 2-fold dilutions of serum in PBS with 1% BSA were added (100 µl/well), and plates were incubated for 1 h at 37°C. After four washes, secondary biotinylated antibodies were added followed by 1 h incubation at 37°C. After six washes, 50 µl/well of peroxidase-conjugated streptavidin (Pharmingen), diluted 1:1000, was added and plates were further incubated for 45 min at room temperature. After a final six washes, the substrate ABTS (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)) in 0.1 M citrate-phosphate buffer containing 0.1% H₂O₂ was added, and plates were incubated for 30-60 min at room temperature. The absorbance was measured at a wavelength of 405 nm.

Statistical Analyses - For apoAI binding experiments, an unpaired t-test was used to determine if there was any significant difference in the apoAI binding ability of wildtype and mutant SOF proteins. For latex bead experiments, a one way ANOVA using Bartlett's test for equal variance was used to determine whether there was any significant variation in the median number of beads attached to or taken up by HEp-2 cells, followed by a Tukey's Multiple Comparison Test for individual comparison of adherence and internalisation mediated by two different proteins. For immunization and challenge experiments, a Kruskal-Wallis test was used to determine whether there was any significant variation in the median titers of the four groups of antisera. Dunn’s Multiple Comparison test was used for individual comparison of two groups of antisera. Difference in survival curves was determined by log rank test. All statistics were performed using GraphPad Prism version 4.02 (GraphPad Software Inc., San Diego, CA, USA).

RESULTS

SOF is a unique multi-functional protein, capable of binding fibronectin via a C-terminal domain designated FnBD (8,24) and apoAI via an N-terminal domain (12) (Fig. 1A). The N-terminal domain of SOF (SOFΔFn) has been shown to mediate adhesion to HEp-2 cells and promote HEp-2 cell invasion by whole GAS cells. In order to assess the contribution of the OF activity of SOF in the processes of HEp-2 epithelial cell adhesion and invasion, deletion mutagenesis was used to eliminate the OF activity of recombinant rSOF75ΔFn. Deletion was undertaken to remove between 22 and 63 amino acid residues of the rSOF75ΔFn protein (between P 148 and K211; P 210 and E 232; K231 and D 286; V285 and E 315). Each of the rSOF75ΔFn deletion mutants lacked OF activity (Fig. 1B). The rSOF75ΔFnDEL[P210→E232] mutant was also found to lack OF activity when incubated in human serum or human HDL (Fig. 2). In order to delineate specific amino acid residues that contribute to OF activity, site directed mutagenesis to alanine was undertaken on 52 amino acids of SOF75ΔFn that are 100% conserved in 16 different SOF sequences (Supplementary Fig. 1 and Supplementary Table 1). A mutant form of rSOF75ΔFn with attenuated OF activity (100 fold reduction in activity) was constructed by simultaneously substituting 5 amino acids with alanine (D218; S 226; K 228; M 229; E 232) (Fig. 1C). The rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] protein has attenuated OF activity when incubated with either human serum or human HDL (Fig. 2). In order to determine if the loss or attenuation of OF activity was due to a decrease in the apoAI binding capacity of SOF, the ability of rSOF75ΔFnWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] and rSOF75ΔFnDEL[P210→E232] to bind biotinyulated
apoAI was assayed (Fig. 2D). There was no significant decrease in apoAI binding by the mutant proteins, suggesting that the loss of OF activity occurs via an alternative mechanism.

The impact of the mutations to rSOF75ΔFn on protein structure was analyzed using far-UV CD spectroscopy. rSOF75ΔFnWT had a CD emission spectrum typical of proteins containing both α helices and β sheets, with a characteristic minimum at ~220 nm, a second larger minimum at ~207 nm and a maximum at 190 nm (34). Of the minimum at ~220 nm, a second larger minimum at 204 nm for rSOF75ΔFnWT and a maximum at 190 nm (34). Of the rSOF75ΔFnDEL mutant proteins generated, rSOF75ΔFnDEL[K231→D286] could not be purified for structural analysis. Far-UV CD spectra obtained for rSOF75ΔFnDEL[P148→K211], rSOF75ΔFnDEL[P210→E232] and rSOF75ΔFnDEL[V285→D315] indicate perturbation to the secondary structure of the proteins. The rSOF75ΔFnWT is predicted to contain 27% alpha helicity, with a predicted 24% alpha helical content in rSOF75ΔFnDEL[P148→K211], 21% in rSOF75ΔFnDEL[P210→E232] and 22% in rSOF75ΔFnDEL[V285→D315]. A concomitant shift towards a more disordered structure was observed for each deletion mutant, as indicated by a shift in the 207 nm minima to a shorter wavelength of 204 nm for rSOF75ΔFnDEL[P148→K211] and rSOF75ΔFnDEL[P210→E232] and 205.5 nm for rSOF75ΔFnDEL[V285→D315] (Fig. 3) (34, 35). In contrast to the loss of secondary structural elements in the rSOF75ΔFnDEL mutants, the rSOF75ΔFnDEL[P218A-S226A-K228A-M229A-E232A] mutant had increased secondary structure when compared to rSOF75ΔFnWT, with an increase in predicted alpha helicity from 27% to 29% (Fig. 3).

In order to assess the direct contribution of the OF activity of SOF in the processes of HEp-2 epithelial cell adhesion and invasion, the ability of latex beads coated with wildtype OF-positive, mutant OF-negative and OF-attenuated forms of the rSOF75ΔFn protein to bind to the human pharyngeal epithelial cell line HEp-2 was assayed. These studies indicate that the SOFΔFn domain mediates attachment to HEp-2 cells, with the latex beads coated with rSOF75ΔFnWT adhering to HEp-2 cells in numbers equivalent to latex beads coated with the full length rSOF75 (p>0.05), and significantly more latex beads coated with rSOF75ΔFnWT adhering to HEp-2 cells than latex beads coated with a protein encompassing only the fibronectin binding domain of the SOF protein (rFNBD) (p<0.01). Furthermore, this HEp-2 adherence mediated by the SOFΔFn domain is not dependent on OF activity, with latex beads coated with rSOF75ΔFnDEL[Δ218A-S226A-K228A-M229A-E232A] (attenuated OF activity) and rSOF75ΔFnDEL[P148→K211] (abolished OF activity) mediating adherence at the same level as the rSOF75ΔFnWT protein (p>0.05) (Fig. 4A, C). Latex beads coated with rSOF75ΔFnDEL[P210→E232] and rSOF75ΔFnDEL[V285→D315] have a significantly reduced capacity to attach to HEp-2 cells when compared to rSOF75ΔFnWT (p<0.01), however, there were significantly more latex beads coated with rSOF75ΔFnDEL mutants attached to HEp-2 cells than were observed with the BSA control (p<0.01). It has been previously demonstrated that the SOFΔFn domain of SOF possesses pro-invasive properties when expressed on the surface of non-invasive GAS strains or non-invasive Lactococcus lactis (13). However, while the SOFΔFn promotes epithelial cell invasion in these backgrounds, this study has shown that the SOFΔFn protein domain is not sufficient per se to mediate intracellular invasion of HEp-2 cells (Fig. 4B, C). However, while it is apparent that the N-terminus of SOF does not directly mediate epithelial cell invasion, it may be concluded that this domain enhances the epithelial cell invasion by full-length SOF, in comparison to the FnBD alone. A significantly greater proportion of latex beads coated with rSOF75 were found to be intracellular (57.1%) than latex beads coated with FnBD alone (31.8% intracellular) (p<0.01) (Fig. 4B).

While SOF is a protective antigen in murine vaccination studies, the capacity of SOF to opacify serum raises questions about its use in humans. The capacity to knock-out OF activity while retaining the structural and functional integrity of the molecule may be a requirement for further evaluation of SOF as a human vaccine candidate. To this end, the protective efficacy of rSOF75ΔFnWT, rSOF75ΔFnDEL[P218A-S226A-K228A-M229A-E232A] and the corresponding deletion mutant rSOF75ΔFnDEL[P210→E232] were assessed in a murine model of lethal GAS challenge.
rSOF75ΔFnWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] and rSOF75ΔFnDEL[P210→E232] all elicited significantly elevated titres of anti-rSOF75ΔFnWT serum IgG (p<0.001; p<0.01, p<0.01) (Fig. 5A). In concordance with the results of Courtney et al. (15), mice immunized with rSOF75ΔFnWT showed significantly increased survival when challenged with the SOF-positive M49 GAS strain 591 compared with PBS control mice (p = 0.0069). While mice immunized with rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A], and the corresponding deletion mutant rSOF75ΔFnDEL[P210→E232] showed increased survival when compared to the control mice, this increase was not statistically significant (p>0.05) (Fig. 5B). While Courtney et al. (15) have previously shown that parenteral immunization with rSOF2ΔFn protects against lethal systemic challenge with an M2 GAS strain, this is the first study to show that immunization with SOF can protect against lethal challenge with a heterologous GAS strain.

DISCUSSION

SOF is a unique multifunctional protein which may contribute to GAS pathogenesis by virtue of its abilities to interact with a variety of components of plasma and the extracellular matrix. A number of GAS surface proteins have a role in promoting host epithelial cell invasion including SfbI (36,37), M protein (31,38,39), PrtF2 (40,41), FbaA (42) and SOF (13). M protein and SfbI mediate intracellular invasion via two distinct pathways, both of which are dependant on fibronectin binding. M protein-mediated ingestion of GAS depends on co-engagement of the CD46 receptor and fibronectin via separate domains of the M protein; fibronectin in turn acts as a bridging molecule binding α5β1 receptors at the host epithelial cell surface. (43-46). The formation of the M protein-fibronectin-α5β1 complex and engagement of the CD46 receptor results in intracellular signaling cascades that lead to cytoskeletal rearrangement for ingestion of the bacteria (31,47). As opposed to M protein, SfbI in turn acts as a bridging molecule binding α5β1 receptors at the host epithelial cell surface. (43-46). The formation of the M protein-fibronectin-α5β1 complex and engagement of the CD46 receptor results in intracellular signaling cascades that lead to cytoskeletal rearrangement for ingestion of the bacteria (31,47). As opposed to M protein, SfbI requires only an interaction with fibronectin to trigger intracellular invasion, since the two fibronectin binding domains on SfbI co-operatively bind fibronectin which in turn binds α5β1 integrins on the host cell surface (44,45). The resultant complex triggers the formation and recruitment of caveosomes which may allow GAS to persist within host cells without exposure to the acidic environment of phagosomes or lysosomes (48). While it has been clearly demonstrated through specific gene deletion that SOF, PrtF2 and FbaA are mediators of intracellular invasion of epithelial cells, the mechanism via which these surface protein mediate internalisation is not known. The work of Timmer et al. (13), using SOFΔFn expressed at the surface of SOF-negative GAS and the heterologous species L. lactis, found that the N-terminal OF domain of SOF contributes to epithelial cell invasion independently of the C-terminal fibronectin binding domain. However, using latex beads coated with SOF protein, we demonstrate that the N-terminal OF domain is not intrinsically sufficient to mediate epithelial cell invasion, but will significantly enhance intracellular invasion in the presence of FnBD. Different GAS strains express a wide array of surface anchored proteins that interact with fibronectin, the M49 GAS strain used in the experiments of Timmer et al. (13) expresses both FBP54 and PrtF2 (40,49). Thus, in this case the SOFΔFn expressed on the surface of M49 GAS may enhance cellular uptake, as the requirement for fibronectin binding may be achieved by FBP54 and PrtF2 expressed at the surface of the M49 GAS cells. However, the exogenous addition of rFnBD does not induce internalisation of rSOFΔFn (results not shown), suggesting that fibronectin binding must be coupled at the surface of the latex bead or GAS cell for enhanced internalisation to occur.

Incubation of cells with exogenous rSOFΔFn does not enhance uptake of GAS cells but inhibits internalisation in a concentration dependant manner (13), suggesting that the interaction of the N-terminal domain of SOF with the epithelial cell surface occurs via a specific receptor on the surface of HEp-2 cells.

We have previously demonstrated (13) that the N-terminal OF domain of SOF mediates tight adherence to epithelial cells. Thus, SOFΔFn mediated adherence to the surface of epithelial cells most likely occurs via a mechanism independent of that required for the opacity reaction. The finding that these mutations clearly diminished the ability of SOF to opacify HDL but
did not alter its binding to apoA1 indicated that other functions of SOF related to the opacity reaction were altered. Recent data suggest that SOF is a heterodivalent fusogenic protein that opacifies HDL by binding and crosslinking HDL particles resulting in the displacement of apoA1, fusion of the HDL particles, and the extrusion of a delipidated HDL particle (50). This mechanism produces a very large lipid particle that is enriched in cholesterol esters and essentially depleted of apolipoproteins. Thus, we propose that the described mutations of SOF alter the opacity reaction by interfering with one or more of these processes. The expression of multifunctional proteins at the surface of GAS is a common theme. For instance, M protein, SfbI, and the hyaluronic acid capsule each have dual functions in epithelial cell interactions and phagocytosis resistance (31,36-39,51-54), while glyceraldehyde-3-phosphate dehydrogenase functions as a glycolytic enzyme and binds multiple serum proteins including plasmin and fibronectin (55,56). SOF joins an increasing list of multifunctional surface proteins of GAS.

As an immunogenic surface protein of GAS, SOF is a candidate vaccine antigen. While SOF was shown to lack protective efficacy against mucosal challenge when administered intranasally (57), SOF is a promising vaccine against systemic infection as parenteral immunization of mice with SOF2ΔFn protects against lethal intraperitoneal challenge (15). Unlike in Europe and the United States, where the throat is often the primary tissue reservoir, the skin is the major site of infection among a number of populations in which GAS infection is endemic including the Australian aboriginal population (58), populations of India and Trinidad, American Indians and Polynesians living in New Zealand (59-61). Thus, there is a need for protective antigens for use in areas such as the tropical north of Australia, where the skin is the primary route of GAS entry. Two of the prime vaccine candidates from the surface proteome of GAS, SfbI and the conserved C-terminal epitopes of M protein, while effective at eliciting protection against mucosal colonization, have proven ineffectual at reducing the rate of mortality due to systemic GAS infection in murine models (62,63). While SOF has proven to be protective against systemic infection, it is not known what physiological effect the interactions between HDL and SOF would have upon the human host following vaccination. It would be prudent to eliminate the OF activity of the SOF protein to ensure undesirable side effects do not occur. To this end the OF attenuated (rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A]) and corresponding OF negative (rSOF75ΔFnDEL[P210→E232]) mutants generated in this study were examined to determine the protective efficacy of the mutants against lethal systemic GAS infection. Unfortunately, while the mutant proteins remained immunogenic, the structural alterations introduced upon mutagenesis may have prevented accessibility of protective epitopes or altered the protective epitopes such that mice immunized with rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL were not significantly protected. Other protective epitopes in streptococcal antigens including the M protein of GAS and the Group B streptococcus polysaccharide capsule and alpha C protein (64,65), are conformational in nature and as such will only be protective if presented to the host immune system in their native conformation. In addition, maintenance of the conformational structure may enhance the immune response to epitopes of M proteins of GAS (66). The protective efficacy of the main protective epitope of SOF may have been altered by a loss of conformation associated with mutagenesis performed in this study. This study has shown that SOF can protect against intraperitoneal challenge by a heterologous GAS strain. This data in conjunction with previous findings that antiserum against one serotype of GAS was bactericidal for multiple GAS serotypes (15) suggests that SOF contains common protective epitopes.

The SOF protein is a virulence determinant in GAS with affinity for multiple serum proteins including fibrinogen (67), fibronectin (8,24) and apoAI (12). Additionally, SOF plays a role in epithelial cell adhesion and invasion (9,13) and phagocytosis resistance (68). This study has shown that the N-terminus of SOF mediates binding to HEp-2 cells and delineates this binding activity from the ability of the N-terminus of SOF to opacify serum. This study is the first to indicate that vaccination with SOF can protect against infection by a heterologous GAS serotype in an animal model.
REFERENCES

1. Tart, A. H., Walker, M. J., and Musser, J. M. (2007) Trends Microbiol. 15, 318-325
2. Walker, M. J., McArthur, J. D., McKay, F., and Ranson, M. (2005) Trends Microbiol. 13, 308-313
3. Cunningham, M. W. (2000) Clin. Microbiol. Rev. 13, 470-511.
4. Goodfellow, A. M., Hibble, M., Talay, S. R., Kreikemeyer, B., Currie, B. J., Sripakash, K. S., and S. C. G. (2000) J. Clin. Microbiol. 38, 389-392
5. Beall, B., Gherardi, G., Lovgren, M., Facklam, R. R., Forwick, B. A., and Tyrrell, G. J. (2000) Microbiology 146, 1195-1209
6. Jeng, A., Sakota, V., Li, Z., Datta, V., Beall, B., and Nizet, V. (2003) J. Bacteriol. 185, 1208-1217.
7. Kreikemeyer, B., Martin, D. R., and Chhatwal, G. S. (1999) FEMS Microbiol. Lett. 178, 305-311
8. Rakonjac, J. V., Robbins, J. C., and Fischetti, V. A. (1995) Infect. Immun. 63, 622-631.
9. Oehmeke, S., Podbielski, A., and Kreikemeyer, B. (2004) Infect. Immun. 72, 4302-4308
10. Saravani, G. A., and Martin, D. R. (1990) FEMS Microbiol. Lett. 56, 35-39.
11. Katerov, V., Lindgren, P. E., Totolian, A. A., and Schalen, C. (2000) Curr. Microbiol. 40, 149-156.
12. Courtney, H. S., Zhang, Y. M., Frank, M. W., and Rock, C. O. (2006) J. Biol. Chem. 281, 5515-5521
13. Timmer, A. M., Kristian, S. A., Datta, V., Jeng, A., Gillen, C. M., Walker, M. J., Beall, B., and Nizet, V. (2006) Mol. Microbiol. 62, 15-25
14. Courtney, H. S., Hasty, D. L., Li, Y., Chiang, H. C., Thacker, J. L., and Dale, J. B. (1999) Mol. Microbiol. 32, 89-98
15. Courtney, H. S., Hasty, D. L., and Dale, J. B. (2003) Infect. Immun. 71, 5097-5103
16. Hyka, N., Dayer, J. M., Modoux, C., Kohno, T., Edwards, C. K., 3rd, Roux-Lombard, P., and Burger, D. (2001) Blood 97, 2381-2389
17. Levels, J. H., Abraham, P. R., van Barreveld, E. P., Meijers, J. C., and van Deventer, S. J. (2003) Infect. Immun. 71, 3280-3284
18. Grunfeld, C., Marshall, M., Shigenaga, J. K., Moser, A. H., Tobias, P., and Feingold, K. R. (1999) J. Lipid. Res. 40, 245-252
19. Emancipator, K., Csako, G., and Elin, R. J. (1992) Infect. Immun. 60, 596-601
20. Levine, D. M., Parker, T. S., Donnelly, T. M., Walsh, A., and Rubin, A. L. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 12040-12044
21. Tada, N., Sakamoto, T., Kagami, A., Mochizuki, K., and Kurosaka, K. (1993) Mol. Cell. Biochem. 119, 171-178
22. Srinivas, R. V., Venkatachalapathil, Y. V., Rui, Z., Owens, R. J., Gupta, K. B., Srinivas, S. K., Anantharamaiah, G. M., Segrest, J. P., and Compans, R. W. (1991) J. Cell. Biochem. 45, 224-237
23. Owens, B. J., Anantharamaiah, G. M., Kahlon, J. B., Srinivas, R. V., Compans, R. W., and Segrest, J. P. (1990) J. Clin. Invest. 86, 1142-1150
24. Kreikemeyer, B., Talay, S. R., and Chhatwal, G. S. (1995) *Mol. Microbiol.* 17, 137-145
25. Sanderson-Smith, M. L., Walker, M. J., and Ranson, M. (2006) *J. Biol. Chem.* 281, 25965-25971
26. Gillen, C. M., Towers, R. J., McMillan, D. J., Delvecchio, A., Sriprakash, K. S., Currie, B., Kreikemeyer, B., Chhatwal, G. S., and Walker, M. J. (2002) *Microbiology* 148, 169-178
27. Ionescu, R. M., and Matthews, C. R. (1999) *Nat. Struct. Biol.* 6, 304-307
28. Reymond, M. T., Merutka, G., Dyson, H. J., and Wright, P. E. (1997) *Protein Sci.* 6, 706-716
29. Schmid, F. X. (1989) in *Protein Structure: A Practical Approach* (Creighton, T. E., ed), pp. 251-284, IRL Press at Oxford University Press, Oxford
30. Chen, Y. H., Yang, J. T., and Martinez, H. M. (1972) *Biochemistry* 11, 4120-4131
31. Dombek, P. E., Cue, D., Sedgewick, J., Lam, H., Ruschkowski, S., Finlay, B. B., and Cleary, P. P. (1999) *Mol. Microbiol.* 31, 859-870.
32. Molinari, G., Talay, S. R., Valentini-Weigand, P., Rohde, M., and Chhatwal, G. S. (1997) *Infect. Immun.* 65, 1357-1363.
33. Podbielski, A., Woinshnik, M., Leonard, B. A. B., and Schmidt, K. H. (1999) *Mol. Microbiol.* 31, 1051-1064
34. Venyaminov, S. Y., and Yang, J. T. (1996) in *Circular dichroism and the Conformational Analysis of Biomolecules* (Fasman, G. D., ed), 1st Ed., pp. 69-107, Plenum Press, New York
35. Freifelder, D. (1982) *Physical Biochemistry. Applications to Biochemistry and Molecular Biology*, 2nd Ed., W. H. Freeman and Company, New York
36. Jadoun, J., Ozeri, V., Burstein, E., Skutelsky, E., Hanski, E., and Sela, S. (1998) *J Infect Dis* 178, 147-158.
37. Okada, N., Tatsuno, I., Hanski, E., Caparon, M., and Sasakawa, C. (1998) *Microbiology* 144, 3079-3086.
38. Cue, D., Dombek, P. E., Lam, H., and Cleary, P. P. (1998) *Infect. Immun.* 66, 4593-4601.
39. Cue, D., Lam, H., and Cleary, P. P. (2001) *Microb. Pathog.* 31, 231-242.
40. Kreikemeyer, B., Oehmeke, S., Nakata, M., Hoffrogge, R., and Podbielski, A. (2004) *J. Biol. Chem.* 279, 15850-15859
41. Terao, Y., Kawabata, S., Nakata, M., Nakagawa, I., and Hamada, S. (2002) *J. Biol. Chem.* 277, 47428-47435.
42. Terao, Y., Kawabata, S., Kunitomo, E., Murakami, J., Nakagawa, I., and Hamada, S. (2001) *Mol. Microbiol.* 42, 75-86.
43. Rezzcallah, M. S., Hodges, K., Gill, D. B., Atkinson, J. P., Wang, B., and Cleary, P. P. (2005) *Cell Microbiol.* 7, 645-653
44. Molinari, G., Rohde, M., Guzman, C. A., and Chhatwal, G. S. (2000) *Cell Microbiol.* 2, 145-154.
45. Ozeri, V., Rosenshine, I., Mosher, D. F., Fassler, R., and Hanski, E. (1998) *Mol. Microbiol.* 30, 625-637.
46. Cue, D., Southern, S. O., Southern, P. J., Prabhakar, J., Lorelli, W., Smallheer, J. M., Mousa, S. A., and Cleary, P. P. (2000) *Proc. Natl. Acad. Sci. U. S. A.* 97, 2858-2863.
47. Purushothaman, S. S., Wang, B., and Cleary, P. P. (2003) Infect. Immun. 71, 5823-5830
48. Rohde, M., Muller, E., Chhatwal, G. S., and Talay, S. R. (2003) Cell Microbiol. 5, 323-342
49. Kawabata, S., Kunitomo, E., Terao, Y., Nakagawa, I., Kikuchi, K., Totsuka, K., and Hamada, S. (2001) Infect. Immun. 69, 924-930.
50. Gillard, B. K., Courtney, H. S., Massey, J. B., and Pownall, H. J. (2007) Biochemistry In press.
51. McArthur, J., and Walker, M. J. (2006) Mol. Microbiol. 59, 1-4
52. Medina, E., Molinari, G., Rohde, M., Haase, B., Chhatwal, G. S., and Guzman, C. A. (1999) J. Immunol. 163, 3396-3402.
53. Schrager, H. M., Alberti, S., Cywes, C., Dougherty, G. J., and Wessels, M. R. (1998) J. Clin. Invest. 101, 1708-1716.
54. Wessels, M., Goldberg, J., Moses, A., and DiCesare, T. (1994) Infect. Immun. 62, 433-441
55. Pancholi, V., and Fischetti, V. A. (1992) J. Exp. Med. 176, 415-426.
56. Winram, S. B., and Lottenberg, R. (1996) Microbiology 142, 2311-2320.
57. Schulze, K., Medina, E., and Guzman, C. A. (2006) Vaccine 24, 1446-1450
58. Currie, B. J., and Carapetis, J. R. (2000) Australas. J. Dermatol. 41, 139-143; quiz 144-135.
59. Svartman, M., Potter, E. V., Mohammed, I., Cox, R., Poon-King, T., and Earle, D. P. (1980) in Streptococcal diseases and the immune response. (Read, S. E., and Zabriskie, J., eds), pp. 669-679, Academic Press, New York, NY
60. Finger, F., Rossaak, M., Umstaetter, R., Reulbach, U., and Pitt, R. (2004) N. Z. Med. J. 117, U847
61. Bisno, A. L. (1995) in Principles and Practice of infectious diseases (Mandell, G. L., Bennet, R. G., and Dolin, R., eds) Vol. 2, pp. 1786-1799, Churchill Livingstone, New York, NY
62. Bessen, D., and Fischetti, V. A. (1988) Infect. Immun. 56, 2666-2672
63. McArthur, J., Medina, E., Mueller, A., Chin, J., Currie, B. J., Sripriaksh, K. S., Talay, S. R., Chhatwal, G. S., and Walker, M. J. (2004) Infect. Immun. 72, 7342-7345
64. Gravekamp, C., Horensky, D. S., Michel, J. L., and Madoff, L. C. (1996) Infect. Immun. 64, 3576-3583
65. Zou, W., Mackenzie, R., Therien, L., Hirama, T., Yang, Q., Gidney, M. A., and Jennings, H. J. (1999) J. Infect. Immunol. 163, 820-825
66. Relf, W. A., Cooper, J., Brandt, E. R., Hayman, W. A., Anders, R. F., Pruksakorn, S., Currie, B., Saul, A., and Good, M. F. (1996) Pept. Res. 9, 12-20
67. Courtney, H. S., Dale, J. B., and Hasty, D. L. (2002) Curr. Microbiol. 44, 236-240.
68. Courtney, H. S., Hasty, D. L., and Dale, J. B. (2006) Mol. Microbiol. 59, 936-947

FOOTNOTES

1 Recipient of an Australian Research Council Postgraduate Award
2 Supported by research funds from the Department of Veterans Affairs (H.S.C.)
3 Author to whom correspondence should be addressed: School of Biological Sciences, University of Wollongong, Wollongong, NSW, 2522, Australia. Tel: 0061-2-4221 3439; Fax: 0061-2-4221 4135; E-mail: mwalker@uow.edu.au
The abbreviations used are: GAS, group A streptococcus; SOF, Serum opacity factor; OF, opacity factor; apoAI, apolipoprotein AI; LPS, lipopolysaccharide; SOFΔFn, N-terminal SOF domain; FnBD, C-terminal fibronectin binding domain; WT, wildtype.
FIGURE LEGENDS

FIGURE 1: The domain structure, opacity factor activity and adherence phenotypes of SOF, rSOF75, rSOF75ΔFnWT, and the rSOF75ΔFn mutants generated in this study. A, Schematic representation of the SOF75 protein. SS, signal sequence; FnBD, fibronectin binding domain; MSD, membrane spanning domain. The domain mediating opacity factor (OF) activity is indicated by a bracket. Boxes represent the domains encompassed by the rSOF75 proteins used in this study. B, Opacity factor phenotype of wildtype and mutant forms of the rSOF75ΔFn peptide as indicated by the serum agarose overlay method.

FIGURE 2: The OF activity and apoAI binding capacity of wildtype and mutant forms of rSOF75ΔFn. A, OF activity over 24 h was determined by adding 1 μg/ml of either rSOF75ΔFnBDWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL[P210→E232] to human serum and recording the A405nm at timed intervals. B, C, the opacification of serum (B) or HDL (C) as a function of protein concentration. Human serum or purified human HDL was treated with the indicated concentration of protein for 24 h and the absorbance determined at 405 nm. D, binding of biotinylated apoAI by either rSOF75ΔFnBDWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL[P210→E232].

FIGURE 3: rSOF75ΔFn mutants have perturbed secondary structure. The spectra of wildtype rSOF75ΔFn (solid line) compared to mutant forms of recombinant SOF75ΔFn (dotted line). A, rSOF75ΔFnDEL[P148→K211]; B, rSOF75ΔFnDEL[P210→E232]; C, rSOF75ΔFnDEL[V285→D315]; D, rSOF75ΔFnDEL[P218A-S226A-K228A-M229A-E232A]. All proteins exhibit CD emission spectra characteristic of proteins containing both α helices and β sheets, displaying a characteristic minimum at ~220 nm, a second minimum at ~207 nm and a maximum at 190 nm. CD spectra in A, B and C show a shift in the latter minimum to a shorter wavelength indicating an increase in the proportion of the protein having disordered structure.

FIGURE 4: SOFΔFn promotes association of latex beads to HEp-2 cells independent of OF activity. A, The total number of SOF coated latex beads per 10 HEp-2 cells. SOF coated latex beads were incubated with HEp-2 cells for 4 hours in DMEM HEPES supplemented with 1% FCS. Asterisks indicate adherence significantly lower than that mediated by the recombinant full length SOF, rSOF75 (p<0.001) B, C, Binding and uptake of SOF-coated latex beads by HEp-2 cells. Following incubation with latex beads, internal and external beads were differentiated using double immunofluorescence confocal microscopy. External beads were labeled by incubation with SOF specific rabbit anti-serum, followed by goat anti-rabbit Alexa-488 conjugated antibody (green). Internal beads were labelled by subsequently permeabilizing the cells using 0.1% Triton X-100, and subsequently incubating the cells with SOF-specific rabbit antiserum, followed by goat anti-rabbit Alexa-633 conjugated antibody (red). C, A sample of images obtained using double immunofluorescence microscopy. Binding and uptake mediated by rSOF75, rFnBD and rSOF75ΔFn peptides is shown. Binding mediated by SOF75ΔFn[D218A-S226A-K228A-M229A-E232A] with attenuated OF activity and rSOF75ΔFnDEL[P148→K211] with abrogated OF activity is also shown.

FIGURE 5: The murine response to parenteral immunization with wildtype and mutant forms of rSOF75ΔFn and subsequent lethal intraperitoneal challenge. A, Antibody titres directed against rSOF75ΔFnWT 28 days post intravenous immunisation with either rSOF75ΔFnWT, rSOF75ΔFn [D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL[P210→E232]. Bars represent specific IgG present in the serum of control and vaccinated mice, with results expressed as geometric means, error bars represent standard error of the mean (n=10). Asterisks indicate
titres significantly greater than the control. B, Survival of intravenously immunized mice after lethal challenge with a heterologous *S. pyogenes* strain. Mice (n=10) vaccinated with either rSOF75ΔFnWT, rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A] or rSOF75ΔFnDEL[P210→E232] were challenged with ~1x10⁹ CFU of virulent M49 *S. pyogenes* strain 591. Mortality was recorded daily. Significance was determined using the log rank test.

**SUPPLEMENTARY FIGURE 1:** ClustalW alignment of the amino acid sequence of the N-terminal domain of SOF from 16 different GAS strains. 100% conserved amino acid residue are highlighted in black.
Figure 1

A

SS

OPACITY FACTOR DOMAIN

LPASG motif

FnBD

rSOF75

rSOF75ΔFnWT

B

rSOF75ΔFnWT

rSOF75ΔFnWT

[P148→K211]

rSOF75ΔFnWT

[P210→E232]

rSOF75ΔFnWT

[K231→D286]

rSOF75ΔFnWT

[ P285→E315]

OPACITY FACTOR ACTIVITY

+ - - - - ATTENUATED
Figure 2

(A) SERUM
Opacity Reaction (A405nm)
0.00 0.25 0.50 0.75 1.00
Time (hours)
0 5 10 15 20 25
Protein Concentration (μg/ml)
0.01 0.1 1 10

(B) SERUM
Opacity Reaction (A405nm)
0.00 0.2 0.4 0.6 0.8 1.0
Protein Concentration (μg/ml)
0.01 0.1 1 10

(C) HDL
Opacity Reaction (A405nm)
0.00 0.2 0.4 0.6 0.8 1.0
Protein Concentration (μg/ml)
0.01 0.1 1 10

(D) Binding to ApoAI (A650 nm)

- rSOF75ΔFnWT
- rSOF75ΔFn[D218A-S226A-K228A-M229A-E232A]
- rSOF75ΔFnDEL[P210→E232]

Figure 2
Figure 3

A  rSOF75ΔFr[ΔP148→K211]

B  rSOF75ΔFr[ΔP210→E232]

C  rSOF75ΔFr[ΔV285→E315]

D  rSOF75ΔFr[ΔD218A-S226A-K228A-M229A-E232A]
Figure 4

A

B

C

Figure 4
Figure 5

A

Anti-rSOF75\(\rightarrow\)Fn\(\text{WT}\) titre

- PBS control
- rSOF75\(\rightarrow\)Fn\(\text{WT}\)
- rSOF75\(\rightarrow\)Fn\([D218A-S226A-K228A-M229A-E232A]\)
- rSOF75\(\rightarrow\)Fn\([P210\rightarrow E232]\)

B

Percent survival

- PBS control
- SOF\(\Delta\)Fn\(\text{WT}\)
- SOF\(\Delta\)Fn\([D218A-S226A-K228A-M229A-E232A]\)
- SOF\(\Delta\)Fn\([P210\rightarrow E232]\)

*p < 0.01
*p > 0.05
*p > 0.05
Supplementary Table 1: Forward primers used for PCR construction of SOF site-directed mutants.
Underlined sequences indicate introduced mutations. For site-directed mutants containing four or more mutations not encoded in a single primer, mutations were sequentially introduced using previously mutated DNA as a template.

| Introduced mutation | Forward Primer |
|---------------------|----------------|
| R<sup>147</sup>-Q<sup>150</sup>-D<sup>160</sup>-D<sup>165</sup>/A | 5’ CTTAAAAGTAATGCGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| D<sup>218</sup>/A | 5’ GAAATTGAGCAAGGTGGGCGTGTATAGGGCC 3’ |
| M<sup>219</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| D<sup>224</sup>/A | 5’ GATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| S<sup>228</sup>/A | 5’ ATGGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| K<sup>228</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| M<sup>229</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| S<sup>226</sup>-K<sup>228</sup>-M<sup>229</sup>-E<sup>232</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| E<sup>232</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| S<sup>226</sup>-K<sup>228</sup>-M<sup>229</sup>-E<sup>232</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| K<sup>238</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| M<sup>242</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| T<sup>247</sup>-T<sup>249</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| R<sup>262</sup>-N<sup>263</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| R<sup>266</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| M<sup>268</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| R<sup>272</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| K<sup>297</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| D<sup>301</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| S<sup>333</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| E<sup>336</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| S<sup>337</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| T<sup>361</sup>-S<sup>363</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| S<sup>462</sup>-R<sup>464</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| N<sup>531</sup>-S<sup>533</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| E<sup>537</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| K<sup>539</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| D<sup>552</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| M<sup>597</sup>-S<sup>599</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| E<sup>599</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| R<sup>615</sup>-D<sup>616</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| S<sup>679</sup>-R<sup>680</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| Y<sup>697</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| K<sup>699</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| L<sup>701</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| V<sup>701</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| L<sup>710</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| K<sup>721</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| R<sup>722</sup>/A | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |

**AvrII restriction sites (CCTAGG)**

| Introduced mutation | Forward Primer |
|---------------------|----------------|
| P<sup>147</sup>-E<sup>149</sup>/P-R | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| R<sup>211</sup>/R | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| T<sup>230</sup>-K<sup>231</sup>/P-R | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| T<sup>230</sup>-K<sup>231</sup>-E<sup>232</sup>/T-L-G | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| V<sup>254</sup>-A<sup>255</sup>-L-G | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |
| A<sup>313</sup>-R<sup>314</sup>-E<sup>315</sup>/A-L | 5’ GCCATGTTGAGCTGACAAAGGTGGGCGTGTATAGGGCC 3’ |